This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q64805347
rdf:type
wikibase:Item
schema:description
clinical trial ensayu clínicu klinisch onderzoek клінічне випробування
rdfs:label
A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
skos:prefLabel
A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
schema:name
A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia
p:P1476
wds:Q64805347-1FEE8283-E50D-4AF4-A479-8AC3BB4556E0
wdt:P1476
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
p:P582
wds:Q64805347-E947B00A-1820-465E-A183-CA6DED7C88FD
wdt:P582
2020-04-20T00:00:00Z
p:P31
wds:Q64805347-C75152BD-0BC4-4763-9139-FC1C94B47E8F
wdt:P31
wd:Q30612
p:P580
wds:Q64805347-01579A5C-37F9-4D2A-A949-8A5A55ECFE9A
wdt:P580
2017-12-22T00:00:00Z
p:P17
wds:Q64805347-19DF9FB0-2679-484A-BEA5-C417CDFDCFB2 wds:Q64805347-E9A71AF9-FEAF-453E-A5F3-DC089E1C30D5 wds:Q64805347-DB776197-2F23-40C1-A55C-6FB76F03E1A1 wds:Q64805347-D7BC4130-1A65-4F8E-AE1F-4E3A2DDAC983 wds:Q64805347-C7355ABC-29DE-4709-9B44-7ED22988C2A7 wds:Q64805347-B362074A-487B-41EF-9FB1-633DAF40B6CF wds:Q64805347-78C9B293-71D4-4BE3-9B5A-6D3433A0F331
wdt:P17
wd:Q219 wd:Q30 wd:Q38 wd:Q183 wd:Q36 wd:Q29 wd:Q212
p:P6153
wds:Q64805347-1736CC52-19B0-4442-8A28-E2EFDFD2E949 wds:Q64805347-385AE9AD-50C4-4D51-9298-DAE35A8861A5 wds:Q64805347-3144B1FA-0061-4D25-A6CF-30FB5CD0F5D2 wds:Q64805347-3A1CD613-88E5-4DAE-A93F-71DAE599FEB9 wds:Q64805347-8AA37E4A-3740-46A9-9706-9F1C0A7422D7 wds:Q64805347-CC849447-FC79-4D24-A3D1-B873A8B52652 wds:Q64805347-F26429BD-7472-48DF-AB68-075C94B7FFFB wds:Q64805347-F1EBDE6F-719B-486A-842F-CB14E2EA4B85 wds:Q64805347-F4185C22-0E6C-47EB-8378-48DE5B03CD2D
wdt:P6153
wd:Q30269522 wd:Q5902531 wd:Q30253940 wd:Q30269674 wd:Q6749295 wd:Q30269791 wd:Q5547686 wd:Q2371388 wd:Q30269707
p:P2899
wds:Q64805347-A412BBEF-01C2-4A67-BF50-F350108EC1D3
wdt:P2899
18
p:P1050
wds:Q64805347-9A61A2F2-F7E9-4DF9-8D5A-0D645832AB24
wdt:P1050
wd:Q41112
p:P1132
wds:Q64805347-42EDE034-242F-4685-B962-B41E9A0D6987
wdt:P1132
234
p:P4135
wds:Q64805347-75BA1D56-5C3D-4782-B54D-D513B6C23F77
wdt:P4135
60
p:P8363
wds:Q64805347-4F9EED1F-34D3-459C-9533-963B7F14D6C6
wdt:P8363
wd:Q78089383
p:P3098
wds:Q64805347-691EEE50-AB6A-433B-B6B4-FFEB1D20133D
wdt:P3098
NCT03382639
p:P6099
wds:Q64805347-5A280BF6-6A1E-4C03-A99D-8A0DA7B1034F
wdt:P6099
wd:Q42824440